CoChat

The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Wiria, Aprilianto E., Hamid, Firdaus, Wammes, Linda J., Kaisar, Maria M. M., May, Linda, Prasetyani, Margaretta A., Wahyuni, Sitti, Djuardi, Yenny, Ariawan, Iwan, Wibowo, Heri, Lell, Bertrand, Sauerwein, Robert, Brice, Gary T., Sutanto, Inge, van Lieshout, Lisette, de Craen, Anton J. M., van Ree, Ronald, Verweij, Jaco J., Tsonaka, Roula, Houwing-Duistermaat, Jeanine J., Luty, Adrian J. F., Sartono, Erliyani, Supali, Taniawati, Yazdanbakhsh, Maria · 2013 · PLoS ONE
Cited by 55

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Helminth infections are proposed to have immunomodulatory activities affecting health outcomes either detrimentally or beneficially. We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy. METHODS AND FINDINGS: A household-based cluster-randomized, double-blind, placebo-controlled trial was conducted in an area in Indonesia endemic for STH. Using computer-aided block randomization, 481 households (2022 subjects) and 473 households (1982 subjects) were assigned to receive placebo and albendazole, respectively, every three months. The treatment code was concealed from trial investigators and participants. Malarial parasitemia and malaria-like symptoms were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported symptoms of allergy in children aged 5-15 years. The general impact of treatment on STH prevalence and body mass index (BMI) was evaluated. Primary outcomes were prevalence of malarial parasitemia and SPT to any allergen. Analysis was by intention to treat. At 9 and 21 months post-treatment 80.8% and 80.1% of the study subjects were retained, respectively. The intensive treatment regiment resulted in a reduction in the prevalence of STH by 48% in albendazole and 9% in placebo group. Albendazole treatment led to a transient increase in malarial parasitemia at 6 months post treatment (OR 4.16(1.35-12.80)) and no statistically significant increase in SPT reactivity (OR 1.18(0.74-1.86) at 9 months or 1.37 (0.93-2.01) 21 months). No effect of anthelminthic treatment was found on BMI, reported malaria-like- and allergy symptoms. No adverse effects were reported. CONCLUSIONS: The study indicates that intensive community treatment of 3 monthly albendazole administration for 21 months over two years leads to a reduction in STH. This degree of reduction appears safe without any increased risk of malaria or allergies. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN83830814.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0057899

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 55

Metadata

Authors
Wiria, A. E., Hamid, F., Wammes, L. J., Kaisar, M. M. M., May, L., Prasetyani, M. A., Wahyuni, S., Djuardi, Y., Ariawan, I., Wibowo, H., Lell, B., Sauerwein, R., Brice, G. T., Sutanto, I., van Lieshout, L., de Craen, A. J. M., van Ree, R., Verweij, J. J., Tsonaka, R., Houwing-Duistermaat, J. J., Luty, A. J. F., Sartono, E., Supali, T., & Yazdanbakhsh, M.
Venue
PLoS ONE
Published
2013-03-19
Volume
8
Issue
3
Pages
e57899
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2028368894
Cited by
55
References
3
FWCI
5.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0057899
The paper
Wiria, A. E., Hamid, F., Wammes, L. J., Kaisar, M. M. M., May, L., Prasetyani, M. A., Wahyuni, S., Djuardi, Y., Ariawan, I., Wibowo, H., Lell, B., Sauerwein, R., Brice, G. T., Sutanto, I., van Lieshout, L., de Craen, A. J. M., van Ree, R., Verweij, J. J., Tsonaka, R., . . . Yazdanbakhsh, M. (2013). The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0057899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.